Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B)
Carcinoma, Renal Cell, receptor tyrosine kinase inhibitor, programmed cell death 1 (PD-1, PD1), programmed cell death ligand 1 (PD-L1, PDL1), Carcinoma, Renal Cell Carcinoma, Pembrolizumab, Lenvatinib, Belzutifan, Pembrolizumab/Quavonlimab, Favezelimab/Pembrolizumab, Coformulation Pembrolizumab/Quavonlimab, Coformulation Favezelimab/Pembrolizumab, Pembrolizumab + MK-4830, Pembrolizumab + Belzutifan, Belzutifan + Lenvatinib, Pembrolizumab + Lenvatinib
Lead Scientist at UCSF
- Arpita Desai
Dr. Arpita Desai is an oncologist who specializes in the treatment of patients with genitourinary cancers, in particular kidney and prostate cancers. She is the Medical Director of the GU Medical Oncology program at UCSF Desai is interested in developing novel imaging and therapeutic strategies in renal cell cancer with the goal of improving outcomes by personalizing therapy.